Phase I/II trial of BL 8040 in combination with sorafenib in AML patients with FLT3-ITD mutation
Phase of Trial: Phase I/II
Latest Information Update: 19 May 2016
At a glance
- Drugs BL 8040 (Primary) ; Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioLineRx
- 19 May 2016 According to a BioLineRx Ltd. media release, the company will present results of this Phase 2a study at the European Hematology Association 21st Congress. Also, the detailed results from this Phase 2a study will be presented at an upcoming US-based scientific conference.
- 10 Mar 2016 Planned initiation date changed from 1 Mar 2015 to 1 Jul 2016, as per BioLineRx media release.
- 17 Dec 2014 New trial record